Travere Therapeutics Stock (NASDAQ: TVTX)

Dernières nouvelles pour Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics Inc

<a href="https://deadline.com/2024/09/scripps-news-layoffs-1236101676/" title="https://deadline.com/2024/09/scripps-news-layoffs-1236101676/">https://deadline.com/2024/09/scripps-news-layoffs-1236101676/</a>

News

'Scripps News To Cut More Than 200 Jobs, Scale Back National News Programming Amid "Difficult" Linear TV Advertising Market' -Deadline Report

Wells Fargo analyst Roger Read maintains Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) with a Overweight and lowers the price target from $196 to $169.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Chevron, Lowers Price Target to $169

AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) has outperformed the market over the past 20 years by 12.03% on an annualized basis producing an average annual return of 20.45%. Currently, AutoZone has a market capitalization of $53.98 billion. 
Buying $100 In AZO: If an investor had bought $100 of AZO stock 20 years ago, it would be worth $4,139.84 today based on a price of $3189.33 for AZO at the time of writing.
<h3>AutoZone's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727451050_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In AutoZone 20 Years Ago Would Be Worth This Much Today

Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) has outperformed the market over the past 5 years by 3.74% on an annualized basis producing an average annual return of 18.08%. Currently, Booz Allen Hamilton has a market capitalization of $20.80 billion. 
Buying $100 In BAH: If an investor had bought $100 of BAH stock 5 years ago, it would be worth $226.69 today based on a price of $161.00 for BAH at the time of writing.
<h3>Booz Allen Hamilton's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727451044_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/09/2024-09-27_08h59_50.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Spending Disappointment</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-spending-disappointment-boj-carry-trade-smci-mc-09272024">click here</a> for an enlarged chart of Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock. The chart of SMCI stock is being used to illustrate the point.</li>
<li>A fortune is to be made in artificial intelligence, but it is not going to be in a straight line. At times, it is going to be treacherous.  It is important to not make mistakes by getting carried away with the momo crowd and listening to momo gurus who have a vested interest that is not your best interest.</li>
<li>The chart shows that momo crowd favorite SMCI fell yesterday on the news of a Department of Justice (DOJ) probe due to allegations of accounting irregularities. A DOJ probe is a serious matter as it is often a criminal probe.</li>
<li>The chart shows that the enthusiasm was at its peak right after SMCI stock was added to S&amp;P 500.</li>
<li>The chart shows from the peak to the low, the stock lost 69% of its value.</li>
<li>The chart shows that the day S&amp;P 500 added SMCI stock, The Arora Report made a bold call. The Arora Report call was that SMCI was worth only $442 &#8211; $486 in the best case. The stock peaked at $1229.  As of this writing in the premarket, SMCI stock is trading at $400.95.  All Arora Report calls are 100% transparent, traceable, and auditable. Members have access to over ten years of archives, including the winners and losers – no cherry picking.</li>
<li>Right now, the momo crowd is sitting on massive losses in SMCI stock. The momo crowd was not able to distinguish between NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Super Micro Computer – the prevailing belief among the momo crowd was that NVDA and SMCI were the same.</li>
<li>The U.S. economy is 70% consumer based. For this reason, prudent investors pay attention to personal income and personal spending.  Just released personal income and spending data is disappointing.  Here are the details of the new personal income and spending data:
<ul>
<li>Personal income came at 0.2% vs. 0.4% consensus.</li>
<li>Personal spending came at 0.2% vs. 0.3% consensus.</li>
</ul>
</li>
<li>PCE is the Fed&#8217;s favorite inflation gauge.&nbsp; Here are the details:
<ul>
<li>PCE came at 0.1% vs. 0.1% consensus.</li>
<li>Core PCE came at 0.1% vs. 0.2% consensus.</li>
<li>In The Arora Report analysis, the data is in line with expectations. As such, this data should have no impact on the stock market.</li>
<li>Even though the stock market pays a lot of attention to PCE, in The Arora Report analysis, economists have become really good at projecting PCE.&nbsp; As such, investors&#8217; expectations, in general, should be that PCE will come in line with consensus.</li>
</ul>
</li>
</ul>
<h3 class="wp-block-heading">Japan</h3>
Bank of Japan (BOJ) actions are very important for U.S. investors. The reason is the carry trade.  In carry trade, funds borrow in yen and invest in the U.S. stock market. Lately, they have been buying AI stocks. Japan's ruling party LDP has chosen Shigeru Ishiba as its new leader. Ishiba is the next prime minister of Japan. In The Arora Report analysis, yen is rallying on the news as Ishiba is a supporter of BOJ.
In The Arora Report analysis, this development is negative for the carry trade and positive for the yen position using ETF Invesco CurrencyShares Japanese Yen Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXY#NYSE">FXY</a>) in The Arora Report&#8217;s ZYX Allocation.
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are neutral in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and NVDA.
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is on track to have the best September ever.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Economics

Markets

General

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

SMCI

TSLA

Personal Income And Spending Disappoint, Super Micro Computer Lesson, BOJ Supporter As Japan PM

WIIM

SMMT

Summit Therapeutics shares are trading lower after Citigroup downgraded the stock from Buy to Neutral but raised its price target from $19 to $23.

Goldman Sachs analyst Kate McShane maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Buy and raises the price target from $876 to $995.

COST

Goldman Sachs Maintains Buy on Costco Wholesale, Raises Price Target to $995

MP Materials shares are trading higher after Baird raised its price target on the stock from $20 to $25.

Wells Fargo analyst Roger Read maintains BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) with a Equal-Weight and lowers the price target from $39 to $35.

Wells Fargo Maintains Equal-Weight on BP, Lowers Price Target to $35

Legal

CHWY

SEC Says Former Chewy Executive Conducted Insider Trading In 2021

Melco Resorts & Entertainment Limited - American Depositary Shares

MLCO

Shares of Macau-linked casino and gaming stocks are trading higher possibly amid continued strength following a report suggesting China will issue up to $284 billion of sovereign debt as part of a stimulus.

Wells Fargo analyst George Kelly maintains Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Equal-Weight and raises the price target from $800 to $850.

Wells Fargo Maintains Equal-Weight on Costco Wholesale, Raises Price Target to $850

Struggling chipmaker Intel Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>)&nbsp;continues to receive <a target="_blank" href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo" rel="noreferrer noopener">takeover proposals from</a> chip companies, the latest being Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) following Qualcomm Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) proposal earlier.
Arm Holdings recently proposed to acquire Intel&#8217;s product unit. However, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-27/arm-rejected-by-intel-after-approaching-it-about-buying-product-unit?sref=TBDibEcD" rel="noreferrer noopener">reports</a> that Intel is not looking to sell the business division.
Intel stock plunged 31% as it failed to capitalize on the artificial intelligence shift, which is something that contract chipmaker Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) excelled at.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/09/41012678/super-micro-unveils-next-gen-servers-powered-by-intels-latest-xeon-chips" rel="noreferrer noopener">Super Micro Unveils Next-Gen Servers Powered by Intel&#8217;s Latest Xeon Chips</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7.png" alt="" class="wp-image-569782" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/27091711/newplot-1-7-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Meanwhile, some reports indicated Intel&#8217;s plans to convert its <a target="_blank" href="https://www.benzinga.com/news/24/09/40897994/whats-going-on-with-intel-stock-on-tuesday" rel="noreferrer noopener">foundry business into</a> an independent unit, including exploring a spinoff into a publicly traded company. The chipmaker also explored divesting stake in the programmable chip unit&nbsp;Altera.
However, Intel&#8217;s recent big wins included a&nbsp;U.S. chipmaking deal from&nbsp;Amazon.Com Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Amazon Web services and the U.S. Chip grant.
The chipmaker also clarified that it would not divest a majority stake in the struggling <a target="_blank" href="https://www.benzinga.com/news/24/09/40941075/whats-going-on-with-autonomous-driving-stock-mobileye-thursday" rel="noreferrer noopener">Israeli autonomous driving company</a> Mobileye Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>), whose stock is down 66% in the last 12 months.
Intel&#8217;s exploration of stake sales to companies like Qualcomm and Arm could hinder its U.S. subsidy over antitrust grounds, the Financial Times <a target="_blank" href="https://www.ft.com/content/ff0ca77d-ad35-45ba-a493-201a26932efb" rel="noreferrer noopener">reports</a>.
Multiple deals including Nvidia&#8217;s proposal to snap Arm Holdings from&nbsp;Softbank Group Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) and Intel&#8217;s&nbsp;Tower Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) deal have succumbed to global regulatory opposition.
The semiconductor sector had a good week, buoyed by the <a target="_blank" href="https://www.benzinga.com/news/earnings/24/09/41046485/whats-going-on-with-nvidia-braodcom-intel-and-other-chip-stocks-on-thursday" rel="noreferrer noopener">key rate cuts</a> in the U.S. and China, an upbeat quarterly print from Micron Technology, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), and continued AI investments from Big Tech companies.
Semiconductor ETFs, Invesco Semiconductors ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSI#NYSE">PSI</a>) and SPDR S&amp;P Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XSD#NYSE">XSD</a>), gained 5%- 7% in the last five days.
Price Action: INTC stock is down 0.04% at $23.91 at the last check on Friday.
Photo via Shutterstock

Tech

Media

INTC

MBLY

PowerShares Exchange-Traded Fund Trust Dynamic Semiconductor Portfolio

QCOM

SFTBF

SFTBY

TSEM

What's Going On With Intel Stock On Friday?

Politics

Multiple Blasts Heard In Beirut, According To Reuters Witness, 'Massive Thick Clouds Of Smoke' Rising From City

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) with a Buy and maintains $10 price target.

Reiteration

LXRX

HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $10 Price Target

On CNBC: Tanger Outlet CEO Discusses Shopping Trends, Consumer Demand

GDRX

PETS

Shares of pharmacy stocks are trading higher. Costco on its earnings call said pharmacy had the strongest sales percentage increase within ancillary businesses, with a double-digit script count growth, which could possibly be lifting the sector.

High-rolling investors have positioned themselves bullish on McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in MCD often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for McDonald's. This is not a typical pattern.
The sentiment among these major traders is split, with 50% bullish and 12% bearish. Among all the options we identified, there was one put, amounting to $107,640, and 7 calls, totaling $441,864.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $145.0 and $440.0 for McDonald's, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in McDonald's's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to McDonald's's substantial trades, within a strike price spectrum from $145.0 to $440.0 over the preceding 30 days.
<h3>McDonald's Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450251_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$163.9</td>
<td>$161.1</td>
<td>$162.7</td>
<td>$145.00</td>
<td>$113.8K</td>
<td>1</td>
<td>7</td>
</tr>
<tr>
<td>MCD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$136.9</td>
<td>$132.5</td>
<td>$134.55</td>
<td>$440.00</td>
<td>$107.6K</td>
<td>0</td>
<td>8</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$2.9</td>
<td>$2.72</td>
<td>$2.9</td>
<td>$305.00</td>
<td>$66.7K</td>
<td>2.4K</td>
<td>355</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>10/04/24</td>
<td>$3.6</td>
<td>$3.45</td>
<td>$3.53</td>
<td>$305.00</td>
<td>$66.3K</td>
<td>2.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>MCD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/04/24</td>
<td>$3.1</td>
<td>$2.96</td>
<td>$3.1</td>
<td>$305.00</td>
<td>$62.0K</td>
<td>2.4K</td>
<td>642</td>
</tr>
</tbody>
</table>

<h3>About McDonald's</h3>
McDonald's is the largest restaurant owner-operator in the world, with 2023 system sales of $130 billion across nearly than 42,000 stores and 115 markets. McDonald's pioneered the franchise model, building its footprint through partnerships with independent restaurant franchisees and master franchise partners around the globe. The firm earns roughly 60% of its revenue from franchise royalty fees and lease payments, with most of the remainder coming from company-operated stores across its three core segments: the United States, internationally operated markets, and international developmental/licensed markets.
Following our analysis of the options activities associated with McDonald's, we pivot to a closer look at the company's own performance.
<h3>Current Position of McDonald's</h3>
<ul>
<li>With a volume of 533,349, the price of MCD is up 0.94% at $306.51. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 31 days.</li>
</ul>
<h3>What Analysts Are Saying About McDonald's</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $303.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs persists with their Neutral rating on McDonald's, maintaining a target price of $325. 
&#x2A; An analyst from TD Cowen has revised its rating downward to Hold, adjusting the price target to $280. 
&#x2A; An analyst from Citigroup persists with their Neutral rating on McDonald's, maintaining a target price of $301. 
&#x2A; Maintaining their stance, an analyst from Baird continues to hold a Outperform rating for McDonald's, targeting a price of $320. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on McDonald's, which currently sits at a price target of $290. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for McDonald's, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On McDonald's

Whales with a lot of money to spend have taken a noticeably bullish stance on Bitdeer Technologies.
Looking at options history for Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 62% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $112,000 and 6, calls, for a total amount of $567,404.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $5.0 and $10.0 for Bitdeer Technologies, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Bitdeer Technologies options trades today is 6177.5 with a total volume of 10,120.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Bitdeer Technologies's big money trades within a strike price range of $5.0 to $10.0 over the last 30 days.
<h3>Bitdeer Technologies Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450246_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$3.8</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$5.00</td>
<td>$285.9K</td>
<td>4.5K</td>
<td>819</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$2.45</td>
<td>$2.25</td>
<td>$2.27</td>
<td>$7.50</td>
<td>$107.1K</td>
<td>9.5K</td>
<td>740</td>
</tr>
<tr>
<td>BTDR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.4</td>
<td>$0.35</td>
<td>$0.35</td>
<td>$7.50</td>
<td>$81.8K</td>
<td>3.4K</td>
<td>2.3K</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$3.0</td>
<td>$2.3</td>
<td>$2.35</td>
<td>$10.00</td>
<td>$54.6K</td>
<td>7.2K</td>
<td>839</td>
</tr>
<tr>
<td>BTDR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.35</td>
<td>$2.05</td>
<td>$2.27</td>
<td>$7.50</td>
<td>$45.4K</td>
<td>9.5K</td>
<td>1.0K</td>
</tr>
</tbody>
</table>

<h3>About Bitdeer Technologies</h3>
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway.
Following our analysis of the options activities associated with Bitdeer Technologies, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Bitdeer Technologies</h3>
<ul>
<li>Currently trading with a volume of 830,932, the BTDR's price is up by 4.06%, now at $8.32. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 45 days.</li>
</ul>
<h3>What The Experts Say On Bitdeer Technologies</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $13.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $13. 
&#x2A; In a cautious move, an analyst from Needham downgraded its rating to Buy, setting a price target of $14. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Bitdeer Technologies, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

BTDR

Bitdeer Technologies's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SAVA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Cassava Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 40% bullish and 46%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $1,182,634, and 4 are calls, for a total amount of $186,612.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $10.0 to $60.0 for Cassava Sciences during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cassava Sciences stands at 624.67, with a total volume reaching 6,170.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cassava Sciences, situated within the strike price corridor from $10.0 to $60.0, throughout the last 30 days.
<h3>Cassava Sciences Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727450241_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.1</td>
<td>$5.05</td>
<td>$5.05</td>
<td>$25.00</td>
<td>$452.0K</td>
<td>153</td>
<td>5</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$7.4</td>
<td>$7.35</td>
<td>$7.35</td>
<td>$30.00</td>
<td>$166.8K</td>
<td>105</td>
<td>234</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$3.15</td>
<td>$2.8</td>
<td>$3.15</td>
<td>$20.00</td>
<td>$164.7K</td>
<td>902</td>
<td>273</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$5.2</td>
<td>$5.15</td>
<td>$5.15</td>
<td>$25.00</td>
<td>$110.7K</td>
<td>153</td>
<td>1.1K</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.55</td>
<td>$8.5</td>
<td>$8.55</td>
<td>$60.00</td>
<td>$85.5K</td>
<td>1.4K</td>
<td>115</td>
</tr>
</tbody>
</table>

<h3>About Cassava Sciences</h3>
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Having examined the options trading patterns of Cassava Sciences, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Cassava Sciences</h3>
<ul>
<li>Trading volume stands at 3,473,313, with SAVA's price down by -13.12%, positioned at $27.69.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cassava Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

SAVA

Cassava Sciences Unusual Options Activity

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yigal Nochomovi...

Upgraded Buy Rating and Target Price for Travere Therapeutics on Filspari's Market Expansion and Approval

In a report released on September 5, Joseph Schwartz from Leerink Partners reiterated a Buy rating on Travere Therapeutics (TVTX – Research Report)...

Buy Rating Affirmed for Travere Therapeutics Following Filspari's Expanded FDA Approval and Positive Market Outlook

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Travere Therapeutics (TVTX – Research Report) on September 6. The company's shares clo...

Travere Therapeutics (TVTX) Gets a Hold from Wells Fargo

Travere Therapeutics (TVTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H....

Buy Rating Affirmed for Travere Therapeutics Amid Proactive HARMONY Study Management and Strong Financial Stance

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Entera Bio (ENTX – Research Report), Legend Biotech ...

Analysts Are Bullish on These Healthcare Stocks: Entera Bio (ENTX), Legend Biotech (LEGN)

Travere slips after pausing late-stage trial's enrollments

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Travere Therapeutics (TVTX – Research Report) today and set a price target of $15.00. T...

TD Cowen Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Adverum Biotechnologies (ADVM – Research Report), Bi...

Analysts Offer Insights on Healthcare Companies: Adverum Biotechnologies (ADVM), Biomea Fusion (BMEA) and Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DENTSPLY SIRONA (XRAY – Research Report) and Travere...

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY) and Travere Therapeutics (TVTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Curis (CRIS – Research Report), Scholar Rock Holding...

Analysts Offer Insights on Healthcare Companies: Curis (CRIS), Scholar Rock Holding (SRRK) and Travere Therapeutics (TVTX)

ADVM

BMEA

CRIS

ENTX

LEGN

SRRK

TVTX

XRAY

Press Releases

Travere Therapeutics to Report Second Quarter 2024 Financial Results

Earnings

Travere Therapeutics Reports Second Quarter 2024 Financial Results

Ligand Reports Second Quarter 2024 Financial Results

Travere Therapeutics to Present at Upcoming Investor Conferences

Health Care

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up

Comments

Travere Therapeutics

Actualités

Dernières nouvelles pour Travere Therapeutics (NASDAQ:TVTX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL